- Home
- CCU vs VRDN Comparison
CCU vs VRDN Comparison
Compare CCU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCU | VRDN |
|---|---|---|
| Founded | 1850 | 2006 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CCU | VRDN |
|---|---|---|
| Price | $11.22 | $19.04 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $12.00 | ★ $35.46 |
| AVG Volume (30 Days) | 120.7K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $7.42 | $13.73 |
| Revenue Next Year | $4.71 | $279.00 |
| P/E Ratio | $18.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.71 | $13.18 |
| 52 Week High | $15.36 | $34.29 |
Technical Indicators
Market Signals| Indicator | CCU | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 55.75 |
| Support Level | $10.81 | $15.58 |
| Resistance Level | $12.18 | $20.44 |
| Average True Range (ATR) | 0.32 | 0.87 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.85 | 48.27 |
Price Performance
Historical ComparisonAbout CCU Compania Cervecerias Unidas S.A.
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.